Fosbait 250 mg (Lanthanum Carbonate)
Price range: 65.00$ through 125.00$
Product Overview Fosbait 250 mg is a prescription phosphate binder for adult patients with chronic kidney disease (CKD) on dialysis. The active ingredient lanthanum carbonate is formulated as a tablet taken with meals to bind dietary phosphorus. Pana
| Active Ingredients | Lanthanum Carbonate |
|---|---|
| Delivery Time | 6 To 15 days |
| Indication | Panacea Biotech Ltd. |
| Manufacturer | Increased phosphate levels in blood |
| Packaging | 30 tablets in 1 strip |
| Strength | 250mg |
| Pack Size | Price | Quantity | |
|---|---|---|---|
| 30 Tablet/s | 65.00$ | ||
| 60 Tablet/s | 93.00$ | ||
| 90 Tablet/s | 125.00$ |
Product Overview
Fosbait 250 mg is a prescription phosphate binder for adult patients with chronic kidney disease (CKD) on dialysis. The active ingredient lanthanum carbonate is formulated as a tablet taken with meals to bind dietary phosphorus. Panacea Biotech Ltd manufactures the product under GMP standards. Each strip contains 30 tablets and is offered in pack sizes of 30 60 and 90 tablets. Shipping takes six to fifteen days after ordering. The medication is listed in the USP monograph and carries a 250 mg strength per tablet.
What is Fosbait 250 mg (Lanthanum Carbonate)
The chemical name of the active component is lanthanum carbonate a salt of the rare earth metal lanthanum combined with carbonate. In tablet form it appears as a white to off‑white tablet imprinted with the brand name Fosbait and the strength 250 mg. Inactive ingredients include microcrystalline cellulose croscarmellose sodium and magnesium stearate which aid in compression and disintegration. The product is listed in the USP monograph and assigned a National Drug Code reflecting its regulatory approval in the United States. Clinical studies indicate that lanthanum carbonate reduces serum phosphate by roughly twenty to thirty percent when used as directed. For detailed scientific information you may refer to the National Institutes of Health (NIH) database on chronic kidney disease https://www.ncbi.nlm.nih.gov/books/NBK538285/
Uses and Benefits
Fosbait is prescribed to lower serum phosphate levels in patients with end‑stage renal disease (ESRD). By binding phosphate in the gastrointestinal tract it helps keep blood phosphate within the target range recommended by nephrology guidelines reducing the risk of vascular calcification bone demineralization and cardiovascular complications. It is often used together with dietary phosphate restriction vitamin D analogs and calcium‑based binders as part of a comprehensive management plan. The tablet formulation allows convenient dosing and the availability of multiple pack sizes supports long‑term therapy without frequent pharmacy visits. More information on hyperphosphatemia management can be found on MedlinePlus https://medlineplus.gov/hyperphosphatemia.html
How It Works
The mechanism of action of lanthanum carbonate relies on its low solubility in the acidic environment of the stomach and duodenum. When taken with food lanthanum ions form insoluble lanthanum phosphate complexes with dietary phosphate preventing its absorption into the bloodstream. This reduction in intestinal phosphate uptake leads to a gradual decline in serum phosphate levels. The drug exhibits minimal systemic absorption and primarily exits the body through fecal elimination. Because it does not significantly affect calcium or magnesium absorption at therapeutic doses it helps maintain overall electrolyte balance. Details on phosphate binding mechanisms are available from Drugs.com https://www.drugs.com/pharmacology/lanthanum-carbonate.html
Dosage Guidelines
The typical dosing regimen for Fosbait 250 mg is one tablet taken with each main meal breakfast lunch and dinner to coincide with phosphate intake. The initial dose is usually one tablet three times daily providing a total daily dose of 750 mg. After four to six weeks the dose may be adjusted based on serum phosphate measurements with a maximum recommended daily dose of six tablets (1500 mg) divided across meals. Patients should swallow the tablet whole avoid crushing and maintain a consistent schedule to ensure steady binding activity throughout the day. Dose titration should be guided by laboratory monitoring of serum phosphate. Official prescribing information is accessible via the FDA drug label portal https://www.fda.gov/drugs/drug-approvals-and-databases/drug-label-information
Side Effects
Adverse events associated with lanthanum carbonate are generally mild and gastrointestinal in nature. The most commonly reported side effects include constipation diarrhea nausea abdominal discomfort and dyspepsia. Rarely patients may experience hypercalcemia when the drug is combined with calcium supplements or develop hypersensitivity reactions such as rash or urticaria. It is important for patients to report any new or worsening symptoms to their healthcare provider promptly especially signs of electrolyte imbalance or gastrointestinal bleeding. Safety data is compiled on the PubMed health summary https://pubmed.ncbi.nlm.nih.gov/29875770/
Warnings and Precautions
Fosbait is contraindicated in patients with known hypersensitivity to lanthanum carbonate or any inactive ingredients. Caution is advised in individuals with a history of bowel obstruction severe constipation or impaired gastrointestinal motility as the tablet may exacerbate these conditions. Concomitant use of iron supplements or certain antibiotics may be affected by the binding properties of lanthanum carbonate requiring an appropriate dosing interval to avoid reduced absorption. Regular laboratory monitoring of serum phosphate calcium and magnesium is recommended to assess therapeutic response and detect emerging electrolyte disturbances. Pregnant or lactating women should consult a physician before use as the safety during pregnancy has not been fully established. Regulatory guidance is outlined by the European Medicines Agency https://www.ema.europa.eu/en
Frequently Asked Questions
What is the recommended starting dose of Fosbait?
The usual starting dose is one tablet taken with each of the three main meals per day. This regimen provides a total daily dose of 750 mg and can be adjusted after four to six weeks based on serum phosphate measurements. For full details see the FDA label https://www.fda.gov/drugs/drug-approvals-and-databases/drug-label-information
Can Fosbait be taken together with other phosphate binders?
Combining Fosbait with other phosphate‑binding agents is generally not recommended unless specifically directed by a physician. Concurrent use may increase the risk of gastrointestinal side effects and affect the absorption of other medications. Always discuss potential drug interactions with your healthcare provider before making any changes to your medication regimen
How long does it take to see a reduction in serum phosphate?
Clinical studies show that a measurable decrease in serum phosphate can be observed within two to four weeks of consistent dosing although the full therapeutic effect may require up to eight weeks. Ongoing monitoring is essential to determine the appropriate dose adjustment and to maintain target phosphate levels
Are there dietary restrictions while on Fosbait?
Patients are advised to follow a low‑phosphate diet in conjunction with medication therapy. Foods high in phosphorus such as dairy products nuts and certain processed foods should be limited. For detailed dietary guidance refer to the NIH Kidney Disease page https://www.niddk.nih.gov/health-information/kidney-disease
Is Fosbait safe for patients with heart disease?
Lanthanum carbonate does not have direct cardiac effects but caution is warranted in patients with severe constipation or bowel obstruction which may indirectly affect overall health. Individuals with a history of heart failure should be monitored for changes in electrolyte balance especially calcium and magnesium levels. Consultation with a cardiologist or nephrologist is recommended for personalized assessment
Related Products
Related Products
In stock
In stock
In stock
In stock
In stock
Product Overview Axipero 5 Mg, produced by Intas Pharmaceuticals Ltd, is an oral tyrosine kinase inhibitor formulated for the treatment of advanced renal cell carcinoma (RCC). The product arrives in a strip containing 14 tablets, each strength 5 Mg.
In stock
In stock
In stock
In stock
In stock
In stock
In stock
Reviews
There are no reviews yet.